The statin family of drugs targets HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway, and has been successfully used in the treatment of hypercholesterolemia for the past four decades. The gene discussed is HMGCR; the disease is familial hypercholesterolemia.